AZN · story · 6 November
AstraZeneca · 10 headlines from 7 outlets, on 6 November 2026.
Reports cover the Indian unit's second-quarter results, citing higher profit and revenue and a share price rally.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Business Upturn is the largest at 7.5, ahead of CNBC TV18 (6.7). Multibagg AI is the smallest at 3.3.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| InvestyWise | 5.3 |
| Business Upturn | 7.5 |
| Multibagg AI | 3.3 |
| CNBC TV18 | 6.7 |
| Univest | 6.7 |
| Sahi | 6.3 |
| TradingView | 5.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| InvestyWise | 3 | +5.3 |
| Business Upturn | 1 | +7.5 |
| Multibagg AI | 2 | +3.3 |
| CNBC TV18 | 1 | +6.7 |
| Univest | 1 | +6.7 |
| Sahi | 1 | +6.3 |
| TradingView | 1 | +5.0 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +7.5 | Indian subsidiary posts strong quarter and shares jump sharply. |
| +6.7 | Indian unit's quarterly profit increased. |
| +6.7 | Indian unit profit up with growth across main therapy areas. |
| +6.7 | Subsidiary's quarterly sales grew strongly. |
| +6.3 | Indian unit's quarterly sales well ahead of prior year. |
| +6.3 | Indian subsidiary reports strong quarterly sales growth. |
| +5.3 | Indian unit reports quarterly profit. |
| +5.0 | Indian unit reports quarterly profit. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +4.2 | Indian unit results and new finance chief covered. |
| 0.0 | Scheduling notice for subsidiary's results meeting. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.